Cellectar Biosciences is a biotechnology business based in the US. Cellectar Biosciences shares (CLRB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.56 – a decrease of 25.36% over the previous week. Cellectar Biosciences employs 20 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.56 |
|---|---|
| 52-week range | $1.82 - $4.45 |
| 50-day moving average | $2.08 |
| 200-day moving average | $2.79 |
| Wall St. target price | $16.33 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.43 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.77 from 2024-11-18
| 1 week (2024-11-13) | -15.31% |
|---|---|
| 1 month (2024-10-18) | -15.31% |
| 3 months (2024-08-20) | -14.90% |
| 6 months (2024-05-20) | -43.99% |
| 1 year (2023-11-20) | -18.06% |
|---|---|
| 2 years (2022-11-18) | -11.06% |
| 3 years (2021-11-19) | 7.55 |
| 5 years (2019-11-20) | 15.7 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -166% |
| Return on equity TTM | -796.67% |
| Profit margin | 0% |
| Book value | $0.13 |
| Market Capitalization | $81.5 million |
TTM: trailing 12 months
We're not expecting Cellectar Biosciences to pay a dividend over the next 12 months.
Cellectar Biosciences's shares were split on a 1:10 basis on 21 July 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellectar Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cellectar Biosciences shares which in turn could have impacted Cellectar Biosciences's share price.
Over the last 12 months, Cellectar Biosciences's shares have ranged in value from as little as $1.82 up to $4.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectar Biosciences's is 1.007. This would suggest that Cellectar Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.